Amarin misses by $0.02, misses on revs
- Reports Q3 (Sep) loss of $0.14 per share, excluding non-recurring items, $0.02 worse than the two analyst estimate of ($0.12); revenues rose 50.8% year/year to $21.32 mln vs the $21.96 mln Capital IQ Consensus.
- Revenue growth in the third quarter of 2015 primarily resulted from increased shipment volumes of Vascepa to wholesalers in support of increased reorders and new orders of Vascepa.